Human Genetics Drives Lipid-Lowering Drug Discovery, Validating PCSK9, APOC3, ANGPTL3 Targets

Cardiovascular disease remains a leading cause of mortality, with dyslipidemia being a major modifiable risk factor. Traditional drug discovery often faces high failure rates in clinical trials. Human genetics offers a powerful approach to de-risk drug development by identifying naturally occurring loss-of-function variants in lipoprotein-regulatory genes. These 'human knockouts' provide invaluable proof-of-concept for novel therapeutic targets, guiding the development of effective lipid-lowering agents and predicting clinical success or failure.

This review synthesizes evidence demonstrating how human genetics, through monogenic family studies and population-based sequencing, identifies individuals with lifelong loss-of-function variants in lipoprotein-regulatory genes. It discusses the application of Mendelian randomization to assess causality of biomarkers like HDL cholesterol and highlights the emergence of RNA-based pharmacology (e.g., siRNAs, ASOs) as a platform for translating genetic insights into durable therapies. The article also touches upon gene-editing approaches and genome-wide association studies (GWAS) in target identification.

Human genetics has successfully identified and validated several key lipid-lowering drug targets. > Loss-of-function variants in PCSK9 led to therapies demonstrating low-density lipoprotein cholesterol lowering with proven cardiovascular benefit. Similarly, targeting APOC3 resulted in approved drugs like olezarsen and plozasiran for triglyceride lowering in familial chylomicronemia syndrome. Intervention against ANGPTL3 yielded evinacumab, approved for homozygous familial hypercholesterolemia. Conversely, Mendelian randomization prospectively identified HDL cholesterol as a noncausal biomarker, accurately predicting the failure of HDL-raising therapies in outcomes trials. RNA-based pharmacology (e.g., N-acetylgalactosamine-conjugated small interfering RNAs, antisense oligonucleotides) has emerged as a pragmatic platform for translating these genetic insights into durable, infrequently dosed therapies, with gene-editing approaches offering potential for permanent interventions. While GWAS and polygenic risk scores have expanded candidate targets, their translational yield remains lower than rare-variant genetics.